Rhumbline Advisers Ptc Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 110,771 shares of PTCT stock, worth $5.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,771
Previous 116,396 4.83%
Holding current value
$5.08 Million
Previous $3.56 Million 15.45%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$30.39 - $37.66 $170,943 - $211,837
-5,625 Reduced 4.83%
110,771 $4.11 Million
Q2 2024

Aug 01, 2024
BUY
$24.69 - $40.12 $180,582 - $293,437
7,314 Added 6.71%
116,396 $3.56 Million
Q1 2024

May 09, 2024
BUY
$24.15 - $31.95 $69,938 - $92,527
2,896 Added 2.73%
109,082 $3.17 Million
Q4 2023

Feb 08, 2024
SELL
$18.07 - $29.37 $14,781 - $24,024
-818 Reduced 0.76%
106,186 $2.93 Million
Q3 2023

Nov 09, 2023
BUY
$22.41 - $41.99 $29,626 - $55,510
1,322 Added 1.25%
107,004 $2.4 Million
Q2 2023

Aug 08, 2023
BUY
$40.4 - $59.1 $93,404 - $136,639
2,312 Added 2.24%
105,682 $4.3 Million
Q1 2023

May 11, 2023
BUY
$38.16 - $48.86 $66,245 - $84,820
1,736 Added 1.71%
103,370 $5.01 Million
Q4 2022

Feb 14, 2023
BUY
$33.53 - $54.79 $101,092 - $165,191
3,015 Added 3.06%
101,634 $3.88 Million
Q3 2022

Nov 10, 2022
BUY
$41.85 - $53.85 $376,650 - $484,650
9,000 Added 10.04%
98,619 $4.95 Million
Q2 2022

Aug 11, 2022
BUY
$25.6 - $45.23 $397,721 - $702,693
15,536 Added 20.97%
89,619 $3.59 Million
Q1 2022

May 12, 2022
SELL
$33.33 - $44.6 $2,399 - $3,211
-72 Reduced 0.1%
74,083 $2.76 Million
Q4 2021

Feb 10, 2022
SELL
$35.36 - $41.86 $31,328 - $37,087
-886 Reduced 1.18%
74,155 $2.95 Million
Q3 2021

Nov 12, 2021
SELL
$37.01 - $44.74 $29,941 - $36,194
-809 Reduced 1.07%
75,041 $2.79 Million
Q2 2021

Aug 05, 2021
BUY
$37.95 - $49.37 $146,638 - $190,765
3,864 Added 5.37%
75,850 $3.21 Million
Q1 2021

May 06, 2021
SELL
$46.8 - $68.92 $402,012 - $592,022
-8,590 Reduced 10.66%
71,986 $3.41 Million
Q4 2020

Feb 10, 2021
BUY
$47.96 - $67.64 $108,293 - $152,731
2,258 Added 2.88%
80,576 $4.92 Million
Q3 2020

Nov 12, 2020
SELL
$45.41 - $57.07 $955,971 - $1.2 Million
-21,052 Reduced 21.19%
78,318 $3.66 Million
Q2 2020

Aug 13, 2020
BUY
$42.56 - $54.98 $439,048 - $567,173
10,316 Added 11.58%
99,370 $5.04 Million
Q1 2020

May 06, 2020
BUY
$32.37 - $59.36 $35,315 - $64,761
1,091 Added 1.24%
89,054 $3.97 Million
Q4 2019

Feb 05, 2020
BUY
$32.22 - $50.07 $230,083 - $357,549
7,141 Added 8.84%
87,963 $4.23 Million
Q3 2019

Oct 23, 2019
BUY
$33.82 - $48.17 $35,747 - $50,915
1,057 Added 1.33%
80,822 $2.73 Million
Q2 2019

Aug 14, 2019
BUY
$35.42 - $45.0 $416,610 - $529,290
11,762 Added 17.3%
79,765 $3.59 Million
Q1 2019

May 01, 2019
BUY
$28.09 - $39.49 $214,158 - $301,071
7,624 Added 12.63%
68,003 $2.56 Million
Q4 2018

Jan 31, 2019
BUY
$29.83 - $46.51 $580,014 - $904,340
19,444 Added 47.5%
60,379 $2.07 Million
Q3 2018

Nov 07, 2018
SELL
$33.9 - $47.77 $93,597 - $131,892
-2,761 Reduced 6.32%
40,935 $1.92 Million
Q2 2018

Aug 06, 2018
BUY
$25.7 - $47.88 $141,427 - $263,483
5,503 Added 14.41%
43,696 $1.47 Million
Q1 2018

May 02, 2018
SELL
$17.46 - $32.59 $17,512 - $32,687
-1,003 Reduced 2.56%
38,193 $1.03 Million
Q4 2017

Feb 09, 2018
SELL
$15.14 - $20.89 $44,011 - $60,727
-2,907 Reduced 6.9%
39,196 $654,000
Q3 2017

Nov 06, 2017
BUY
$16.81 - $21.61 $707,751 - $909,845
42,103
42,103 $842,000

Others Institutions Holding PTCT

# of Institutions
221
Shares Held
78.1M
Call Options Held
144K
Put Options Held
58.7K
View Full List

About PTC THERAPEUTICS, INC.

PTCT Quotes by TradingView
  • Ticker PTCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,541,000
  • Market Cap $3.28B
  • Description
  • PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...
More about PTCT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email